TP3011
TP3011 (CH0793011) is an active metabolite of CH-0793076 and is a potent topoisomerase I inhibitor equipotent as SN38. TP3011 is against cancer cell lines growth with IC50s at the range sub-nanomolar in vitro.
For research use only. We do not sell to patients.
- CAS No.: 534605-74-8
- Formula: C26H26N4O5
- Molecular Weight:474.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Topoisomerase Isoforms
More
Biological Activity
|
Topoisomerase I |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
0.85 nM
Compound: 6c
|
Antiproliferative activity against human HCT116 cells after 3 days
Antiproliferative activity against human HCT116 cells after 3 days
|
[PMID: 19254843] |
| NCI-H460 | IC50 |
8.2 nM
Compound: 6c
|
Antiproliferative activity against human NCI-H460 cells after 3 days
Antiproliferative activity against human NCI-H460 cells after 3 days
|
[PMID: 19254843] |
| QG-56 | IC50 |
8.5 nM
Compound: 6c
|
Antiproliferative activity against human QG56 cells after 3 days
Antiproliferative activity against human QG56 cells after 3 days
|
[PMID: 19254843] |
TP3011 (0-100 nM; 72 hours) (compound 6c) inhibits cell proliferative activities against various human cancer cell lines, producing 50% inhibition (IC50) of cell growth of 0.85 nM; 8.5 nM; and 8.2 nM in HCT116, QG56, and NCI-H460 (NSCLC) cells, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT116, QG56, and NCI-H460 (NSCLC) cells
-
Concentration:0-100 nM
-
Incubation Time:72 hours
-
Result:Was against human cancer cell lines, such as CRC and NSCLC cell lines.
Chemical Information
-
CAS No. 534605-74-8
-
Molecular Weight 474.51
-
Formula C26H26N4O5
-
SMILES
O=C(N1CCCCC)NC2=C3C1=C(CN4C(C(COC([C@@]5(CC)O)=O)=C5C=C46)=O)C6=NC3=CC=C2
-
Synonyms
CH0793011
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Anthoney DA, et al. Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.BMC Cancer. 2012 Nov 21;12:536. [Content Brief]
[2]. Niizuma S, et al. Synthesis of new camptothecin analogs with improved antitumor activities.Bioorg Med Chem Lett. 2009 Apr 1;19(7):2018-21. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz